For the quarter ending 2025-09-30, ATOS had -$6,012K decrease in cash & cash equivalents over the period. -$6,012K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,692 | -15,141 |
| Stock-based compensation | 784 | 1,359 |
| Impairment charge on investment in equity securities | 0 | - |
| Depreciation | 4 | 8 |
| Loss on disposal of assets | 0 | 0 |
| Prepaid materials | -332 | 1,377 |
| Prepaid expenses and other current assets | -495 | -90 |
| Other assets | 329 | 10 |
| Accounts payable | 1,522 | 1,331 |
| Accrued expenses | -211 | 1,281 |
| Payroll liabilities | 71 | -808 |
| Other current liabilities | 19 | 49 |
| Net cash used in operating activities | -6,005 | -13,218 |
| Purchases of property and equipment | 7 | 9 |
| Net cash used in investing activities | -7 | -9 |
| Proceeds from exercise of warrants | 0 | 0 |
| Net cash provided by financing activities | 0 | 0 |
| Net decrease in cash, cash equivalents and restricted cash | -6,012 | -13,227 |
| Cash and cash equivalents at beginning of period | 71,194 | - |
| Cash and cash equivalents at end of period | 51,955 | - |
ATOSSA THERAPEUTICS, INC. (ATOS)
ATOSSA THERAPEUTICS, INC. (ATOS)